CAI — Caris Life Sciences, Inc. stock price, charts and financials

Latest market price

30.92

+2.71+9.61%

Overview Short InterestFilings

CAIQT71Caris Life Sciences, Inc.·NASDAQ

Overview Short InterestFilings

30.92+9.61%

News

Up 9.6% — Caris Life Sciences: Diagnostics Growth With Room To Run (seekingalpha.com).

Medium confidence

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

SYRE+1.66%$92.68 IBRX+6.95%$8.46 APGE-0.01%$135.07 IMVT+3.49%$37.65 ABVX+4.66%$106.99 PCVX+2.72%$60.37 IONS+4.26%$46.75 TGTX+1.11%$56.47

Snapshot

Index	-	P/E	78.36	EPS (ttm)	0.36	Insider Own	-	Shs Outstand	282.68M	Perf Week	17.39%

Market Cap	7.97B	Forward P/E	79.68	EPS next Y	0.35	Insider Trans	-0.27%	Shs Float	11.29M	Perf Month	30.42%

Enterprise Value	7.63B	PEG	1.18	EPS next Q	0.03	Inst Own	-	Short Float	4.84%	Perf Quarter	56.90%

Income	104.00M	P/S	8.05	EPS this Y	-66.38%	Inst Trans	-	Short Ratio	3.30	Perf Half Y	52.16%

Sales	990.00M	P/B	13.47	EPS next Y	192.54%	ROA	8.55%	Short Interest	13.68M	Perf YTD	4.56%

Book/sh	2.09	P/C	10.06	EPS next 5Y	66.27%	ROE	18.77%	52W High	37.86 -18.33%	Perf Year	-14.82%

Cash/sh	2.81	P/FCF	46.97	EPS past 3/5Y	-	ROIC	14.67%	52W Low	15.55 98.80%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	44.09	Sales past 3/5Y	46.55% 22.53%	Gross Margin	69.66%	Volatility	6.50% 5.73%	Perf 5Y	-

Dividend TTM	-	EV/Sales	7.70	EPS Y/Y TTM	113.33%	Oper. Margin	15.49%	ATR (14)	1.40	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	4.88	Sales Y/Y TTM	140.29%	Profit Margin	10.62%	RSI (14)	69.82	Recom	2.50

Dividend Gr. 3/5Y	-	Current Ratio	5.53	EPS Q/Q	99.57%	SMA20	10.19%	Beta	1.30	Target Price	26.00

Payout	0.00%	Debt/Eq	0.66	Sales Q/Q	45.86%	SMA50	34.07%	Rel Volume	0.96	Prev Close	28.21

Employees	1,846	LT Debt/Eq	0.66	Earnings	Nov 04	SMA200	34.40%	Avg Volume	4.48M	Price	30.92

IPO Date	Jun 18, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-139.19% 10.75%	Net Debt/EBITDA	-1.38	Volume	4,302,465	Change	9.61%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-09-26	Initiated	UBS	Neutral	$28
Aug-06-26	Reiterated	Evercore ISI Group	Outperform	$25 → $26
Aug-06-26	Reiterated	BTIG	Buy	$32 → $33
Jul-06-26	Reiterated	Evercore ISI Group	Outperform	$38 → $25
May-08-26	Reiterated	Robert W. Baird		$28 → $22
May-08-26	Reiterated	BTIG	Buy	$45 → $32
Apr-10-26	Initiated	Piper Sandler	Neutral	$21
Feb-17-26	Initiated	Baird	Outperform	$26
Jan-05-26	Reiterated	Evercore ISI	Outperform	$40 → $38
Dec-22-25	Reiterated	Canaccord Genuity	Hold	$28 → $30

Latest News· Times ET

Today

Today06:35AM

Caris Life Sciences: Diagnostics Growth With Room To Runseekingalpha.com

Sep-16-26

Sep-16-2612:56AM

Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?zacks.com

Sep-08-26

Sep-08-2602:30AM

Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detectprnewswire.com

Sep-06-26

Sep-06-2606:11AM

Could Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?Yahoo

Sep-02-26

Sep-02-2604:30AM

Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancerprnewswire.com

Aug-27-26

Aug-27-2606:59AM

Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choiceproactiveinvestors.co.uk

04:30AM

Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancerprnewswire.com

Aug-26-26

Aug-26-2608:58AM

Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market TodayBenzinga

Aug-20-26

Aug-20-2609:02AM

Bessent's Bond Rescue Fizzles, Walmart Craters 9%: Stock Market TodayBenzinga

Aug-11-26

Aug-11-2603:05PM

Caris Life Sciences, Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha

Aug-06-26

Aug-06-2607:01PM

Caris Life Sciences: Guidance Raised, Valuation Still Attractiveseekingalpha.com

Aug-05-26

Aug-05-2605:30PM

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcriptseekingalpha.com

03:11PM

Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2zacks.com

03:04PM

Caris Life Sciences Q2 Earnings Call Highlightsmarketbeat.com

12:05PM

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidanceprnewswire.com

Company

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	990	812	412	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	300	273	233	—	—	—	—	—	—
Gross Profit	690	539	179	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	419	392	322	—	—	—	—	—	—
Research and Development	91	45	114	—	—	—	—	—	—
Other Operating Expense	27	57	0	—	—	—	—	—	—
Operating Income	153	45	-257	—	—	—	—	—	—
Interest Expense	47	57	50	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-1	-56	25	—	—	—	—	—	—
Net Income Before Taxes	104	-68	-282	—	—	—	—	—	—
Income Taxes	0	470	0	—	—	—	—	—	—
Consolidated Net Income	104	-538	-282	—	—	—	—	—	—
Net Income From Continuing Operations	104	-538	-282	—	—	—	—	—	—
Net Income	104	-538	-282	—	—	—	—	—	—
EPS (Recurring)	0.37	-1.91	-2.70	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	0.37	-1.91	-2.70	—	—	—	—	—	—
EPS (Diluted)	0.36	-1.86	-2.70	—	—	—	—	—	—
EBITDA	173	11	-183	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	85.89	—	—	—	—	—	—	—	—
Price To Sales Ratio	8.84	9.37	—	—	—	—	—	—	—
Gross Margin	69.70	66.38	43.45	—	—	—	—	—	—
Operating Margin	15.45	5.54	-62.38	—	—	—	—	—	—
Net Margin	10.51	-66.26	-68.45	—	—	—	—	—	—
Shares Outstanding	283	282	255	—	—	—	—	—	—
Market Capitalization	8,750	7,608	—	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brille Brian J	See Remarks	Sep 17 '26	Option Exercise	2.44	400,000	976,000	630,303	Sep 17
Brille Brian J	See Remarks	Sep 17 '26	Sale	30.33	400,000	12,132,080	230,303	Sep 17
Spetzler David Baxley	President	Sep 04 '26	Sale	24.76	119,212	2,951,117	1,182,871	Sep 04
Spetzler David Baxley	President	Sep 04 '26	Option Exercise	2.44	250,000	610,000	1,302,083	Sep 04
Spetzler David Baxley	President	Sep 03 '26	Sale	24.86	478,000	11,882,989	1,052,083	Sep 04
Spetzler David Baxley	President	Sep 03 '26	Option Exercise	2.44	1,000,000	2,440,000	1,530,083	Sep 04
HALBERT JON	Director	May 15 '26	Buy	14.56	68,000	990,080	704,598	Jul 13
Vacirca Jeff L	Director	May 11 '26	Buy	16.15	31,050	501,426	49,671	May 12
CASTLEMAN PETER M	Director	Jan 09 '26	Option Exercise	18.60	2,500	46,500	18,629	Jan 13
Power Luke Thomas	See Remarks	Dec 11 '25	Option Exercise	2.44	62,250	151,890	161,821	Dec 12
Power Luke Thomas	See Remarks	Dec 11 '25	Sale	26.58	62,250	1,654,462	99,571	Dec 12
Denton John Russel	See Remarks	Nov 07 '25	Buy	24.09	4,184	100,793	9,184	Nov 10
Spetzler David Baxley	President	Nov 07 '25	Buy	23.85	400	9,540	460,777	Nov 10
PHILLIPS T DANNY	Director	Sep 11 '25	Option Exercise	2.44	100,000	244,000	116,129	Sep 12
POSTE GEORGE	Director	Aug 11 '25	Option Exercise	2.44	250,000	610,000	359,754	Aug 13

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.